$ESPR - Long Esperion Therapeutics

Updated
Potential long.

Reported solid phase 1 and phase 2 results for its drug Bempedoic Acid.

Amgen is soon releasing results from a similar drug; if results are promising, ESPR could trend up.

Also forming cup and handle pattern.
Note
Watch for the break over $12.00
Note
DISCLAIMERS:
**The trades seen in this post are in no way intended to be used as advice or guidance for your own trading. These posts are intended for an educational and entertainment purpose only. Day trading and investing in the stock market in general is high risk. Please do not take any comments as direction in trading your own account, and as such, I will not be held liable by any financial losses in your account. **

**I am not a financial advisor. The ideas presented in this post are personal opinions and for entertainment purposes only.**

Also on:

Disclaimer